Pirtobrutinib in CLL: updates from the BRUIN CLL-321 trial

A Unique BTK Inhibitor, Pirtobrutinib for Patients with Pretreated CLL | Jeff Sharman, MD | #ASH24Подробнее

Updates from the Phase I/II BRUIN study: pirtobrutinib in CLLПодробнее

The promise of pirtobrutinib in the treatment of CLLПодробнее

BRUIN CLL-322: pirtobrutinib plus VR vs VR alone in R/R CLLПодробнее

Ongoing trials investigating the efficacy of pirtobrutinib in CLLПодробнее

Some insights into BRUIN CLL-322: a trial in progressПодробнее

Insights into the BRUIN CLL-322 trialПодробнее

BRUIN CLL-322 update: fixed-duration pirtobrutinib plus VR vs VR in patients with R/R CLLПодробнее

BRUIN MCL-321: Pirtobrutinib in BTKi naïve MCLПодробнее

Updates from the BRUIN study – long-term safety of pirtobrutinib in R/R MCLПодробнее

Pirtobrutinib, venetoclax, and rituximab in the treatment of R/R CLL: insights from the BRUIN trialПодробнее

Latest updates from the Phase I/II BRUIN studyПодробнее

Updated results from the BRUIN study: pirtobrutinib in the treatment of MCLПодробнее

Jennifer Woyach, MD, Discusses BRUIN CLL-322 Design, Enrollment ProcessПодробнее

Updates on the Phase I trial of rocbrutinib (LP-168), a novel BTKi, for the treatment of CLLПодробнее

Extensions of BRUIN investigating pirtobrutinib combinations for time-limited CLL treatmentПодробнее

BRUIN study update: analysis of the mechanisms of resistance to pirtobrutinib in CLLПодробнее

BRUIN MCL-321: pirtobrutinib vs investigator choice of BTK inhibitor in BTK inhibitor-naive MCLПодробнее

Pirtobrutinib resistance in CLL: early findingsПодробнее